Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gillis, S.
Right arrow Articles by Polliack, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gillis, S.
Right arrow Articles by Polliack, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 6:777-779, 1995
© 1995 European Society for Medical Oncology

research-article

Acute promyelocytic leukaemia with t(15;17) following treatment of Hodgkin's disease - a report of 4 cases

S. Gillis1, O. Sofer3, O. Zelig1, E. J. Dann1, H. Lotan1, D. Ben Yehuda1, R. Isacson2, E. A. Rachmilewitz1, I. Ben-Bassat3 and A. Polliack1,4

1Department of Haematology, Hadassah Medical Center and Hebrew Univeristy - Hadassah Medical School
2Department of Oncology, Hadassah Medical Center and Hebrew Univeristy - Hadassah Medical School
3Institute of Haematology, The Chaim Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University Tel Aviv, Israel

4Correspondence to: Prof. Aaron Polliack, MBChB, M.D. Head of Lymphoma-Leukaemia Unit Department of Haematology Hadassah University Medical Center POB 12000, Ein Karem Jerusalem, Israel 91120

Background: Therapy-related acute myeloid leukemia (t-AML) is a recognized entity complicating successful therapy for Hodgkin's disease (HD) and other neoplasias after many years. This risk appears to be related to cumulative exposure to alkylating agents and procarbazine, while drugs affecting DNA - topoisomerase II, such as epipodophyllo-toxins and anthracyclines, are also associated with t-AML developing after a much shorter latent period.

Patients and methods: Of 56 patients with t-AML or myelodysplasia seen in our institutes during the period 1980–1994 we encountered 5 patients with acute promyelocytic leukemia (APL) all of whom had t(15;17). Four of these had been treated for HD with both chemotherapy and radiotherapy, and one with radiotherapy alone

Results: To the best of our knowledge these appear to be the first cases of t-AML in HD with cytogenetically proven t(15; 17). Similarly to other cases of t-APL reported after therapy for neoplasias other than HD, these patients also have a relatively favorable prognosis as seen in de-novo APL

Conclusions: Although rare, t-APL should be added to the list of late complications of therapy for HD

acute promyelocytic leukaemia, therapy-related leukaemia, t-APL, Hodgkin's disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
M. Beaumont, M. Sanz, P.M. Carli, F. Maloisel, X. Thomas, L. Detourmignies, A. Guerci, N. Gratecos, C. Rayon, J. San Miguel, et al.
Therapy-Related Acute Promyelocytic Leukemia
J. Clin. Oncol., June 1, 2003; 21(11): 2123 - 2137.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Pulsoni, L. Pagano, F. Lo Coco, G. Avvisati, L. Mele, E. Di Bona, R. Invernizzi, F. Leoni, F. Marmont, A. Mele, et al.
Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience
Blood, August 28, 2002; 100(6): 1972 - 1976.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.